Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer … – Nasdaq
|
Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer …
Nasdaq NanoStilbene, a nanoparticle formulation of pterostilbene is covered for use in cancer immunotherapy under the Company's issued U.S. Patent No.: 9,682,047. Pterostilbene is the active ingredient in the Company's patented ProJuvenol product. StemVacs is … |
